Skip to main content
. 2020 Nov 24;13:1756284820974912. doi: 10.1177/1756284820974912

Table 2.

Cross comparison with historical control.

Our study: n (%) MPACT trial: n (%)
Survival data
Progression-free survival, median (months) 4.8 5.5
Overall survival, median (months) 9.1 8.5
Grade 3 or 4 toxicities
Growth-factor support 48 (66%) 110 (26%)
Anemia 7 (10%) 53 (13%)
Neutropenia 2 (2%) 153 (38%)
Neutropenic fever 0 (0%) 14 (3%)
Thrombocytopenia 3 (3%) 52 (13%)
Neurotoxicity 5 (5%) 70 (17%)
Dose reduction in patients
Nab-paclitaxel 3 (3%) 41%
Gemcitabine 7 (10%) 47%